Stoke Therapeutics, Inc. STOK Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $155.66M-43.4% | $84.22M-34.2% | $83.39M-44.4% | $101.47M-47.6% | $274.82M+53.9% | ||
| $187.89M+128% | $200.45M+125% | $164.92M+84.9% | $146.24M+65.2% | $82.51M— | ||
| $3.23M+4,203% | $494K+559% | $0-100% | $75K0.0% | $75K-86.8% | ||
| $4.45M+236% | $5.94M+256% | $9.25M+73,884% | —— | $1.33M+10,500% | ||
| $10.12M-20.3% | $8.74M-21.4% | $7.75M-21.2% | $13.69M+32.4% | $12.69M+3,058% | ||
| $1.69M+179% | $1.97M+181% | $1.59M+130% | $1.62M+432% | $606K+5,409% | ||
| $366.68M-2.4% | $305.7M+31.3% | $272.44M+7.4% | $269.97M-9.1% | $375.74M+94.4% | ||
| $3.4M-6.0% | $3.15M-19.5% | $3.08M-28.8% | $3.34M-29.9% | $3.61M-31.6% | ||
| $2.49M-34.9% | $3.1M-28.6% | $1.8M-63.5% | $3.22M-41.5% | $3.83M-36.8% | ||
| $67.48M+194% | $106.26M+256% | $80.32M+168% | $107.26M— | $22.99M— | ||
| $443.28M+8.9% | $418.43M+54.1% | $360.26M+22.8% | $384.51M+24.9% | $406.89M+98.3% | ||
| $6.84M+213% | $4.94M+97.7% | $5.87M+136% | $4.31M+9.3% | $2.19M+4.0% | ||
| $6.6M-35.6% | $6.96M— | $8.56M+3.2% | $9.63M-43.2% | $10.26M-59.0% | ||
| $2.43M+3.5% | $3.01M+29.5% | $2.91M+26.5% | $2.3M+0.8% | $2.35M+6.2% | ||
| $40.81M-8.7% | $57.88M+44.5% | $41.73M-16.3% | $38.68M-13.1% | $44.69M+25.6% | ||
| $3.42M-42.5% | $4.15M-13.1% | $1.8M-66.1% | $5.28M-9.3% | $5.95M-6.1% | ||
| $991K-47.1% | $1.14M-54.0% | $1.87M-38.6% | $1.26M-65.2% | $1.87M-55.5% | ||
| $7.59M-37.4% | $8.1M+227% | $10.43M-8.0% | $10.89M-47.0% | $12.13M-58.5% | ||
| $48.4M-14.8% | $65.98M+55.1% | $52.16M-14.8% | $49.57M-23.8% | $56.81M-12.4% | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $942.7M+29.5% | $849.62M+18.0% | $747.44M+4.9% | $736.28M+5.7% | $728.12M+28.1% | ||
| -$547.72M-44.9% | -$497.72M-1.4% | -$439.78M+8.4% | -$401.43M+11.6% | -$377.95M+11.7% | ||
| -$115K-10.6% | $543K+460% | $446K+169% | $96K+740% | -$104K— | ||
| $394.88M+12.8% | $352.46M+53.9% | $308.11M+32.7% | $334.94M+38.0% | $350.07M+149% | ||
| $443.28M+8.9% | $418.43M+54.1% | $360.26M+22.8% | $384.51M+24.9% | $406.89M+98.3% | ||
| $187.89M+128% | $200.45M+125% | $164.92M+84.9% | $146.24M+65.2% | $82.51M— | ||
| $6.88M+36.6% | $4.39M+91.1% | $5.54M+45.5% | $6.87M+60.3% | $5.04M+41.5% | ||
| $2.49M-34.9% | $3.1M-28.6% | $1.8M-63.5% | $3.22M-41.5% | $3.83M-36.8% | ||
| $67.48M+194% | $106.26M+256% | $80.32M+168% | $107.26M— | $22.99M— | ||
| $2.49M-34.9% | $3.1M-28.6% | $1.8M-63.5% | $3.22M-41.5% | $3.83M-36.8% | ||
| $2.49M-34.9% | $3.1M-28.6% | $1.8M-63.5% | $3.22M-41.5% | $3.83M-36.8% | ||
| $23.9M-1.8% | $41.04M+121% | $30.09M+90.8% | $25.62M+76.7% | $24.34M+93.6% | ||
| $10.07M-44.6% | $11.9M-37.3% | $5.76M-81.8% | $8.75M-66.4% | $18.16M-13.2% | ||
| $6.6M-35.6% | $6.96M— | $8.56M+3.2% | $9.63M-43.2% | $10.26M-59.0% | ||
| $3.42M-42.5% | $4.15M-13.1% | $1.8M-66.1% | $5.28M-9.3% | $5.95M-6.1% | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $1.69M+179% | $1.97M+181% | $1.59M+130% | $1.62M+432% | $606K+5,409% | ||
| $10.12M-20.3% | $8.74M-21.4% | $7.75M-21.2% | $13.69M+32.4% | $12.69M+18.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Stoke Therapeutics, Inc.'s total assets?
- Stoke Therapeutics, Inc. (STOK) holds $443.3M in total assets, up 8.9% year over year.
- How much debt does Stoke Therapeutics, Inc. have?
- Stoke Therapeutics, Inc. carries $3.4M in total debt against $394.9M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Stoke Therapeutics, Inc. have?
- Stoke Therapeutics, Inc. holds $155.7M in cash and equivalents.
- Can Stoke Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.99 — current assets exceed current liabilities.
- Where does Stoke Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
